Latest news with #medicalcannabis
Forbes
4 hours ago
- Business
- Forbes
Minnesota's New Marijuana Law Tightens Rules For Employer Drug Tests
Vector illustration of a green marijuana leaf on a white silhouette of Minnesota on a green ... More background. As cannabis laws evolve, so too do the expectations placed on employers. In Minnesota, those expectations just became more exacting, especially when it comes to how companies respond to positive marijuana drug tests. A new law, Senate File 2370 (SF 2370), which became effective May 24, 2025, requires employers to take a more transparent and deliberate approach before disciplining or terminating a registered medical cannabis patient. Article 6, Section 12 of the statute mandates 14 days' written notice before adverse action is taken, and that notice must cite the specific federal law or regulation the employer believes compels such action. Generalized concerns about compliance are no longer enough. This new requirement builds upon the state's earlier efforts to protect both recreational users and medical cannabis patients under House File 100 (HF 100), which legalized adult-use cannabis in 2023. That law barred most employers from testing job candidates for marijuana and extended anti-discrimination protections to registered patients. HF 100 added cannabis to the state's definition of a 'lawful consumable product,' which includes any foods, beverages, or substances permitted and considered safe for human consumption. As a result, employers cannot fire, discipline, or refuse to hire someone solely for using cannabis, whether medical or recreational, off duty and outside the workplace. However, HF 100 did not require employers still eligible to test for marijuana to provide advance notice or explain the legal basis for adverse action. SF 2370 fills that gap by extending those procedural protections to registered medical cannabis patients who test positive. In practice, companies that remain eligible to conduct marijuana testing must tread more carefully when medical cannabis patients are involved. They can no longer rely on general references to federal law. Instead, they must identify the specific statute, regulation, or licensing rule they believe would be violated by continuing to employ or retain a registered patient who tests positive for cannabis. They also need to specify what federal benefit, contract, or license could be at risk. The 14-day notice requirement introduces a procedural check into a process that has traditionally been swift and one-sided. It gives employees and applicants an opportunity to respond, challenge, or resolve the situation without the immediate threat of job loss or discipline. Employers can still enforce drug-free workplace policies, but they must do so with added clarity and caution when medical cannabis is involved. There are exceptions. Employers are not required to delay adverse action if doing so would clearly violate federal law or jeopardize a federal benefit or contract. Under the new statute, however, those exceptions must be invoked with specificity. The days of blanket cannabis prohibitions are giving way to more nuanced, legally defensible policies. Minnesota's approach reflects a broader national trend. States like New York, New Jersey, Montana, and Rhode Island have already limited employment actions based on off-duty cannabis use. But Minnesota's law goes a step further by requiring employers to justify actions taken against medical marijuana patients with documented legal reasoning. That added transparency doesn't eliminate the federal-state conflict, but it shifts some of the burden back to employers to show their hand. Most Minnesota employers are already prohibited from testing for cannabis under HF 100 and, as such, are unlikely to invoke the new procedural standard. However, employers in heavily regulated sectors, such as transportation, defense, and healthcare, may still be subject to federal mandates that require them to take action against employees who test positive. For these organizations, SF 2370 introduces a new requirement: a 14-day written notice to registered medical cannabis patients before taking adverse action, including a citation to the specific federal law or benefit at risk. Employers operating in Minnesota should review and revise their drug testing and adverse action policies immediately. They should also review adverse action procedures and train HR professionals to issue proper notice letters. Legal counsel can help review these procedures, ensure proper documentation, and determine when the new notice requirements apply. As cannabis policy continues to evolve, employers must learn to navigate not just what is legal, but what is fair and defensible. Minnesota's latest law doesn't eliminate complexity, but it raises the bar for transparency and accountability in workplace drug testing decisions.
Globe and Mail
16 hours ago
- Business
- Globe and Mail
Aurora Cannabis Advises of Second False Article from Investing.com
NASDAQ| TSX: ACB EDMONTON, AB, June 19, 2025 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, has become aware of a second instance of misinformation posted on news website,
Yahoo
a day ago
- Business
- Yahoo
Aurora Cannabis Inc (ACB) (Q4 2025) Earnings Call Highlights: Record Revenue Growth and ...
Net Revenue: Increased 27% to $343 million for fiscal 2025. Global Medical Cannabis Revenue: Rose 39%, contributing significantly to total revenue. Adjusted Gross Margin: Improved to 55% from 49% in the previous year. Adjusted EBITDA: Reached a record $49.7 million, up 619% year-over-year. Free Cash Flow: Positive at $9.9 million for fiscal 2025. Cash Balance: $185.3 million with no cannabis business debt. Q4 2025 Net Revenue: $90.5 million, a 34% increase year-over-year. Q4 2025 Adjusted Gross Margin: 62%, up 1,200 basis points from the previous year. Medical Cannabis Net Revenue: Increased 48% to $67.8 million in Q4 2025. Consumer Cannabis Net Revenue: Decreased to $8.2 million from $10.2 million year-over-year. Bevo Plant Propagation Revenue: Increased 32% to $13.8 million year-over-year. Consolidated Adjusted SG&A: Increased 17% to $36.7 million year-over-year. Free Cash Flow for Q4 2025: Positive $2.5 million, an improvement from negative $21.9 million year-over-year. Warning! GuruFocus has detected 4 Warning Signs with ACB. Release Date: June 18, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Aurora Cannabis Inc (NASDAQ:ACB) reported a record-setting year in global medical net revenue, adjusted EBITDA, and positive free cash flow. Net revenue rose 27% to a record $343 million, with global medical cannabis revenue increasing by 39%. The company achieved an improved adjusted gross margin of 55%, up from 49% in the previous year. Aurora Cannabis Inc (NASDAQ:ACB) is debt-free in its cannabis business and holds a strong cash balance of $185 million. The company has a strong international presence, with leading market positions in Canada, Australia, Germany, Poland, and the UK, and is well-positioned to capitalize on global medical cannabis opportunities. Aurora Cannabis Inc (NASDAQ:ACB) experienced headwinds in Poland due to regulatory changes impacting prescription volumes. Consumer cannabis net revenue declined to $8.2 million from $10.2 million in the previous year, reflecting a focus on higher-margin medical cannabis. The company anticipates a temporary decline in some international markets, which may affect Q1 2026 revenue. Adjusted SG&A expenses increased by 17%, driven by higher freight and logistics costs and incremental costs from acquisitions. Despite strong performance, the company faces increasing competition in international markets, which could pressure revenue and margins. Q: Can you provide more details on the temporary decline in some international markets, particularly Poland? A: Miguel Martin, CEO, explained that regulatory changes in Poland affected patient access to prescriptions, impacting market size. However, this is viewed as temporary. Aurora plans to launch high-quality cultivars in Poland to regain market share and sees positive regulatory developments. Germany and the UK continue to grow, with Germany being a significant growth market. Q: How do you feel about the increasing competition in the international cannabis space, and are there any pressures on revenue or margins? A: Miguel Martin, CEO, noted that while there is interest in high-margin markets like Australia and Europe, these markets are challenging to enter due to GMP certification requirements and the need for local infrastructure. Aurora's long-standing presence and resources in these markets provide a competitive advantage. Q: What are the drivers for Aurora's industry-leading gross margins, and where do you see them going? A: Miguel Martin, CEO, highlighted that low production costs and premium product pricing drive high margins. Simona King, CFO, added that yield improvements, cost efficiencies, and a favorable portfolio mix, especially in international medical cannabis, contribute to strong margins. Q: Are there any supply constraints as international markets grow, and how does Aurora plan to address them? A: Miguel Martin, CEO, stated that there have been no supply constraints due to yield improvements and strategic partnerships with third-party cultivators. Aurora continues to invest in facility upgrades to meet demand. Q: What are the prospects for new international markets opening up, and which markets are you focusing on? A: Miguel Martin, CEO, mentioned that in the short term, growth will come from expanding existing markets like Germany, Poland, and the UK. New markets like Switzerland and Austria are emerging, and Aurora is well-positioned to capitalize on these opportunities. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Business
- Yahoo
Aurora Cannabis Inc (ACB) (Q4 2025) Earnings Call Highlights: Record Revenue Growth and ...
Net Revenue: Increased 27% to $343 million for fiscal 2025. Global Medical Cannabis Revenue: Rose 39%, contributing significantly to total revenue. Adjusted Gross Margin: Improved to 55% from 49% in the previous year. Adjusted EBITDA: Reached a record $49.7 million, up 619% year-over-year. Free Cash Flow: Positive at $9.9 million for fiscal 2025. Cash Balance: $185.3 million with no cannabis business debt. Q4 2025 Net Revenue: $90.5 million, a 34% increase year-over-year. Q4 2025 Adjusted Gross Margin: 62%, up 1,200 basis points from the previous year. Medical Cannabis Net Revenue: Increased 48% to $67.8 million in Q4 2025. Consumer Cannabis Net Revenue: Decreased to $8.2 million from $10.2 million year-over-year. Bevo Plant Propagation Revenue: Increased 32% to $13.8 million year-over-year. Consolidated Adjusted SG&A: Increased 17% to $36.7 million year-over-year. Free Cash Flow for Q4 2025: Positive $2.5 million, an improvement from negative $21.9 million year-over-year. Warning! GuruFocus has detected 4 Warning Signs with ACB. Release Date: June 18, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Aurora Cannabis Inc (NASDAQ:ACB) reported a record-setting year in global medical net revenue, adjusted EBITDA, and positive free cash flow. Net revenue rose 27% to a record $343 million, with global medical cannabis revenue increasing by 39%. The company achieved an improved adjusted gross margin of 55%, up from 49% in the previous year. Aurora Cannabis Inc (NASDAQ:ACB) is debt-free in its cannabis business and holds a strong cash balance of $185 million. The company has a strong international presence, with leading market positions in Canada, Australia, Germany, Poland, and the UK, and is well-positioned to capitalize on global medical cannabis opportunities. Aurora Cannabis Inc (NASDAQ:ACB) experienced headwinds in Poland due to regulatory changes impacting prescription volumes. Consumer cannabis net revenue declined to $8.2 million from $10.2 million in the previous year, reflecting a focus on higher-margin medical cannabis. The company anticipates a temporary decline in some international markets, which may affect Q1 2026 revenue. Adjusted SG&A expenses increased by 17%, driven by higher freight and logistics costs and incremental costs from acquisitions. Despite strong performance, the company faces increasing competition in international markets, which could pressure revenue and margins. Q: Can you provide more details on the temporary decline in some international markets, particularly Poland? A: Miguel Martin, CEO, explained that regulatory changes in Poland affected patient access to prescriptions, impacting market size. However, this is viewed as temporary. Aurora plans to launch high-quality cultivars in Poland to regain market share and sees positive regulatory developments. Germany and the UK continue to grow, with Germany being a significant growth market. Q: How do you feel about the increasing competition in the international cannabis space, and are there any pressures on revenue or margins? A: Miguel Martin, CEO, noted that while there is interest in high-margin markets like Australia and Europe, these markets are challenging to enter due to GMP certification requirements and the need for local infrastructure. Aurora's long-standing presence and resources in these markets provide a competitive advantage. Q: What are the drivers for Aurora's industry-leading gross margins, and where do you see them going? A: Miguel Martin, CEO, highlighted that low production costs and premium product pricing drive high margins. Simona King, CFO, added that yield improvements, cost efficiencies, and a favorable portfolio mix, especially in international medical cannabis, contribute to strong margins. Q: Are there any supply constraints as international markets grow, and how does Aurora plan to address them? A: Miguel Martin, CEO, stated that there have been no supply constraints due to yield improvements and strategic partnerships with third-party cultivators. Aurora continues to invest in facility upgrades to meet demand. Q: What are the prospects for new international markets opening up, and which markets are you focusing on? A: Miguel Martin, CEO, mentioned that in the short term, growth will come from expanding existing markets like Germany, Poland, and the UK. New markets like Switzerland and Austria are emerging, and Aurora is well-positioned to capitalize on these opportunities. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Germany Legal Cannabis Market Report 2025-2030: Competitive Analysis of The Cronos Group, Organigram, Tilray, Canopy Growth, Aurora Cannabis, SynBiotic, Cansativa, Four 20 Pharma, and Avextra Pharma
Germany's legal cannabis market, valued at USD 37.15M in 2024, is expected to reach USD 85.64M by 2030, driven by rising acceptance, medical applications, and tech innovations. Key growth factors include government support, increased medical cannabis use, and advanced cultivation technologies. Ideal for market analysis and strategy planning. German Legal Cannabis Market Dublin, June 18, 2025 (GLOBE NEWSWIRE) -- The "Germany Legal Cannabis Market Size, Share & Trends Analysis Report by Source (Hemp, Marijuana), Derivatives (CBD, THC, Others), End-use with Growth Forecasts, Key Companies and Competitive Analysis, 2025-2030" report has been added to German Legal Cannabis Market was valued at USD 37.15 million in 2024, and is projected to reach USD 85.64 million by 2030, rising at a CAGR of 14.09%. Factors such as rising social acceptance of cannabis, growing medical applications of cannabis, increasing R&D & technological innovation, and the introduction of new cultivation technologies are expected to drive the cannabis industry in the country. For instance, in February 2024, according to data published in Reuters, 4.5 million individuals are estimated to use cannabis in Germany. Furthermore, favorable government initiatives and reimbursement policies fuel the market growth. For instance, according to data published by the Federal Union of German Associations of Pharmacists (ABDA), the number of prescriptions for medical cannabis for Statutory Health Insurance (SHI)-insured patients in Germany was 338,500 in 2022. Furthermore, according to the same source, 14,840 Kg of cannabis was delivered to pharmacies for medicinal purposes in growing awareness among people regarding the therapeutic applications of cannabis and the launch of online cannabis prescription platforms drive market growth. For instance, in September 2023, Cantourage Group SE, a Berlin-based company, introduced Telecan, a telemedicine platform for medical cannabis, under the guidance of Florian Wesemann, a medical doctor. The platform offers a simple and convenient way for potential patients to access cannabis therapy. In recent years, there has been a significant rise in the usage of cannabis and its derivatives in Germany. The medical application of CBD has gained immense popularity, leading to the development of policies for its distribution and use by the government. Moreover, conferences and various events being organized for cannabis industry leaders drive market growth. For instance, the International Cannabis Business Conference was to be held in Berlin in April 2024, Germany's biggest annual gathering of influential political and cannabis business cannabis industry has witnessed the development of new techniques and technologies that aid in its cultivation, and these advancements are expected to boost market growth. The demand for technologically advanced cannabis production has led to the optimization of resources by cultivators. This, coupled with the increased utilization of hemp and marijuana in various sectors, such as personal care & cosmetics, pharmaceuticals, nutraceuticals, and food, & beverages, has impelled market growth. In addition, the use of cannabis and its derivatives by various businesses as a raw material for manufacturing products is projected to drive market growth over the forecast Legal Cannabis Market Report Highlights By source, the hemp segment dominated the market with the highest revenue share of 84.50% in 2024. Hemp covers an extensive range of products, including supplements, nutritional powders, beverages, protein & nutrition bars, animal feed, and pet food. By derivatives, the CBD segment dominated the market with the largest revenue share of 63.61% in 2024. CBD is the non-psychoactive compound found in the cannabis plant, and its adoption is increasing for a wide range of health benefits. By end use, the industrial use segment dominated the market with a revenue share of 80.26% in 2024. This report addresses: Market intelligence to enable effective decision-making Market estimates and forecasts from 2018 to 2030 Growth opportunities and trend analyses Segment and regional revenue forecasts for market assessment Competition strategy and market share analysis Product innovation listings for you to stay ahead of the curve Companies Featured The major companies featured in this Germany Legal Cannabis market report include: The Cronos Group Organigram Holding, Inc Tilray Brands Canopy Growth Corporation Aurora Cannabis SynBiotic Cansativa GmbH DEMECAN Four 20 Pharma Avextra Pharma Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $37.15 Million Forecasted Market Value (USD) by 2030 $85.64 Million Compound Annual Growth Rate 14.0% Regions Covered Germany Key Topics Covered: Chapter 1. Methodology and ScopeChapter 2. Executive Summary2.1. Market Outlook2.2. Segment Outlook2.3. Competitive InsightsChapter 3. Germany Legal Cannabis Market Variables, Trends, and Scope3.1. Market Lineage Outlook3.2. Germany Legal Cannabis Market - Market Dynamics3.3. Germany Legal Cannabis: Market Analysis Tools3.4. Current Market Trends in Cannabis Industry3.5. Regulatory Scenario3.6. Cannabis Consumption Pattern Analysis3.7. Guidelines and Requirements for Cannabis Cultivation3.8. Cannabis Facility Design and Equipment Requirements3.9. Reimbursement Policies in the GermanyChapter 4. Germany Legal Cannabis Market: Segment Analysis, By Source, 2018-2030 (USD Million)4.1. Definition and Scope4.2. Source Market Share Analysis, 2024 & 20304.3. Segment Dashboard4.4. Germany Legal Cannabis Market, by Source, 2018 to 20304.5. Marijuana4.5.1. Marijuana Market Estimates and Forecasts, 2018-2030 (USD Million)4.5.2. Flower4.5.3. Oil and Tinctures4.6. Hemp4.6.1. Hemp Market Estimates and Forecasts, 2018-2030 (USD Million)4.6.2. Hemp Oil4.6.3. Industrial HempChapter 5. Germany Legal Cannabis Market: Segment Analysis, By Derivative, 2018-2030 (USD Million)5.1. Definition and Scope5.2. Derivative Market Share Analysis, 2024 & 20305.3. Segment Dashboard5.4. Germany Legal Cannabis Market, by Derivative, 2018 to 20305.5. CBD5.6. THC5.7. OthersChapter 6. Germany Legal Cannabis Market: Segment Analysis, By End Use, 2018-2030 (USD Million)6.1. Definition and Scope6.2. End Use Market Share Analysis, 2024 & 20306.3. Segment Dashboard6.4. Germany Legal Cannabis Market, by End Use, 2018 to 20306.5. Medical Use6.5.1. Medical Market Estimates and Forecasts, 2018-2030 (USD Million)6.5.2. Cancer6.5.3. Chronic Pain6.5.4. Depression and Anxiety6.5.5. Arthritis6.5.6. Diabetes6.5.7. Glaucoma6.5.8. Migraines6.5.9. Epilepsy6.5.10. Multiple Sclerosis6.5.11. AIDS6.5.12. Amyotrophic Lateral Sclerosis6.5.13. Alzheimers's6.5.14. Post Traumatic Stress Disorder (PTSD)6.5.15. Parkinson's6.5.16. Tourettes6.5.17. Others6.6. Recreational Use6.7. Industrial UseChapter 7. Germany Legal Cannabis Market: Competitive Landscape7.1. Participant's Categorization7.2. Company Market Position Analysis, 20247.3. Strategy Mapping7.4. Company Profiles The Cronos Group Organigram Holding, Inc Tilray Brands Canopy Growth Corporation Aurora Cannabis SynBiotic Cansativa GmbH DEMECAN Four 20 Pharma Avextra Pharma For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment German Legal Cannabis Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
